Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Jean‐Marie Grouin et al.|The Lancet Respiratory Medicine|2023Cited by 76
Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)Peter Pickkers, Derek C. Angus, Kristie Bass et al.|Intensive Care Medicine|2024Cited by 67
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trialBruno François, Sébastien Gibot, Simon Lambden et al.|EClinicalMedicine|2023Cited by 18